Article Data

  • Views 259
  • Dowloads 148

Original Research

Open Access

Combination of fertility preservation strategies in young women with recently diagnosed cancer

  • M. Huser1,*,
  • J. Zakova1,
  • L. Smardova2
  • I. Crha1
  • P. Janku1
  • R. Hudecek1
  • P. Ventruba1

1Department of Obstetrics and Gynecology, Brno, Czech Republic

2Department of Internal Medicine and Hematooncology Brno University Hospital and Masaryk University School of Medicine, Brno, Czech Republic

DOI: 10.12892/ejgo20120142 Vol.33,Issue 1,January 2012 pp.42-50

Published: 10 January 2012

*Corresponding Author(s): M. Huser E-mail:


Background/Aims: The study describes clinical management and outcomes of currently available fertility preservation techniques in a set of 154 young female cancer patients. Methods: Patients in reproductive age with newly diagnosed cancer were offered embryo or oocyte cryopreservation, ovarian tissue cryopreservation and the administration of GnRH analogues during chemotherapy. Particular attention was given to the technical aspects and clinical application of these fertility preservation techniques. Results: During the study period (2004-2009), 154 young female cancer patients were offered fertility preservation counseling. Patient's average age was 29.4 years and average parity was 0.7 children. Administration of GnRH analogues (n = 123, 79.9%) and ovarian tissue cryopreservation (n = 15, 9.7%) were the most commonly used fertility preservation strategies. In 20 cases (16.1%), the combination of several fertility preservation techniques was offered to individually selected patients. Conclusions: Combination of fertility preservation techniques gives young cancer patients the best chance for future fertility and should be concentrated in specialized centers.


Cancer; infertility; Fertility preservation; Oocyte cryopreservation; Ovarian tissue cryopreservation

Cite and Share

M. Huser,J. Zakova,L. Smardova,I. Crha,P. Janku,R. Hudecek,P. Ventruba. Combination of fertility preservation strategies in young women with recently diagnosed cancer. European Journal of Gynaecological Oncology. 2012. 33(1);42-50.


[1] Huser M., Smardova L., Ventruba P., Mayer J.: “Impact of oncological treatment on human reproduction”. Klin. Onkol., 2010, 23, 165.

[2] McLaughlin E.A., McIver S.C.: “Awakening the oocyte: controlling primordial follicle development”. Reproduction, 2009, 137, 1.

[3] Woodruff T.K.: “The emergence of a new interdiscipline: oncofertility”. Cancer Treat. Res., 2007, 138, 3.

[4] Jeruss J.S., Woodruff T.K.: “Preservation of fertility in patients with cancer”. N. Engl. J. Med., 2009, 360, 902.

[5] Oktay K., Buyuk E., Davis O., Yermakova I., Veeck L., Rosenwaks Z.: “Fertility preservation in breast cancer patients: IVF and embryo cryopreservation after ovarian stimulation with tamoxifen”. Hum. Reprod., 2003, 18, 90.

[6] Porcu E., Bazzocchi A., Notarangelo L., Paradisi R., Landolfo C., Venturoli S.: “Human oocyte cryopreservation in infertility and oncology”. Curr. Opin. Endocrinol. Diabetes Obes., 2008, 15, 529.

[7] Blumenfeld Z., Avivi I., Eckman A., Epelbaum R., Rowe J.M., Dann E.J.: “Gonadotropin-releasing hormone agonist decreases chemotherapy-induced gonadotoxicity and premature ovarian failure in young female patients with Hodgkin lymphoma”. Fertil. Steril., 2008, 89, 166.

[8] Huser M., Crha I., Ventruba P., Hudecek R., Zakova J., Smardova L. et al.: “Prevention of ovarian function damage by a GnRH analogue during chemotherapy in Hodgkin lymphoma patients”. Hum. Reprod., 2008, 23, 863.

[9] Badawy A., Elnashar A., El-Ashry M., Shahat M.: “Gonadotropinreleasing hormone agonists for prevention of chemotherapyinduced ovarian damage: prospective randomized study”. Fertil. Steril., 2009, 91, 694.

[10] Dal Prato L., Borini A., Cattoli M., Bonu M.A., Sciajno R., Flamigni C.: “Endometrial preparation for frozen-thawed embryo transfer with or without pretreatment with gonadotropin-releasing hormone agonist”. Fertil. Steril.,, 2002, 77, 956.

[11] Fabbri R., Porcu E., Marsella T., Rocchetta G., Venturoli S., Flamigni C.: “Human oocyte cryopreservation: new perspectives regarding oocyte survival”. Hum. Reprod., 2001, 16, 411.

[12] Kuwayama M., Vajta G., Kato O., Leibo S.P.: “Highly efficient vitrification method for cryopreservation of human oocytes”. Reprod. Biomed Online, 2005, 11, 300.

[13] Meirow D., Levron J., Eldar-Geva T., Hardan I., Fridman E., Zalel Y. et al.: “Pregnancy after transplantation of cryopreserved ovarian tissue in a patient with ovarian failure after chemotherapy”. N. Engl. J. Med., 2005, 353, 318.

[14] Amorim C.A., Van Langendonckt A., David A., Dolmans M.M., Donnez J.: “Survival of human pre-antral follicles after cryopreservation of ovarian tissue, follicular isolation and in vitro culture in a calcium alginate matrix”. Hum. Reprod., 2009, 24, 92.

[15] Isachenko V., Isachenko E., Reinsberg J., Montag M., Braun F., van der Ven H.: “Cryopreservation of human ovarian tissue: effect of spontaneous and initiated ice formation”. Reprod. Biomed. Online, 2008, 16, 336.

[16] Donnez J., Dolmans M.M., Demylle D., Jadoul P., Pirard C., Squifflet J. et al.: “Livebirth after orthotopic transplantation of cryopreserved ovarian tissue”. Lancet, 2004, 364, 1405.

[17] Ferme C., Eghbali H., Meerwaldt J.H., Rieux C., Bosq J., Berger F. et al.: “Chemotherapy plus involved-field radiation in earlystage Hodgkin’s disease”. N. Engl. J. Med., 2007, 357, 1916.

[18] Lamar C.A., DeCherney A.H.: “Fertility preservation: state of the science and future research directions”. Fertil. Steril., 2009, 91, 316.

[19] Bedaiwy M.A., Shahin A.Y., Falcone T.: “Reproductive organ transplantation: advances and controversies”. Fertil. Steril., 2008, 90, 2031.

[20] Oktay K., Hourvitz A., Sahin G., Oktem O., Safro B., Cil A., Bang H.: “Letrozole reduces estrogen and gonadotropin exposure in women with breast cancer undergoing ovarian stimulation before chemotherapy”. J. Clin. Endocrinol. Metab., 2006, 91, 3885.

[21] Schoolcraft W.B., Keller J.L., Schlenker T.: “Excellent embryo quality obtained from vitrified oocytes”. Reprod. Biomed. Online, 2009, 19, 820.

[22] Revel A., Revel-Vilk S., Aizenman E., Porat-Katz A., Safran A., Ben-Meir A. et al.: “At what age can human oocytes be obtained?”. Fertil. Steril., 2009, 92, 458.

[23] Donnez J., Dolmans M.M.: “Cryopreservation of ovarian tissue: an overview”. Minerva Med., 2009, 100, 401.

[24] Demeestere I., Simon P., Buxant F., Robin V., Fernandez S.A., Centner J. et al.: “Ovarian function and spontaneous pregnancy after combined heterotopic and orthotopic cryopreserved ovarian tissue transplantation in a patient previously treated with bone marrow transplantation: case report”. Hum. Reprod., 2006, 21, 2010.

[25] American College of Obstetrics and Gynecology: “Essential elements of informed consent for elective oocyte cryopreservation: a Practice Committee opinion”. Fertil. Steril., 2008, 90, S134.

[26] Donnez J., Squifflet J., Van Eyck A.S., Demylle D., Jadoul P., Van Langendonckt A., Dolmans M.M.: “Restoration of ovarian function in orthotopically transplanted cryopreserved ovarian tissue: a pilot experience”. Reprod. Biomed. Online, 2008, 16, 694.

[27] Xu M., Barrett S.L., West-Farrell E., Kondapalli L.A., Kiesewetter S.E., Shea L.D., Woodruff T.K.: “In vitro grown human ovarian follicles from cancer patients support oocyte growth”. Hum. Reprod., 2009, 24, 2531.

[28] Blumenfeld Z., Avivi I., Linn S., Epelbaum R., Ben-Shahar M., Haim N.: “Prevention of irreversible chemotherapy-induced ovarian damage in young women with lymphoma by a gonadotrophin-releasing hormone agonist in parallel to chemotherapy”. Hum. Reprod., 1996, 11, 1620.

[29] Dann E.J., Epelbaum R., Avivi I., Ben Shahar M., Haim N., Rowe J.M., Blumenfeld Z.: “Fertility and ovarian function are preserved in women treated with an intensified regimen of cyclophosphamide, adriamycin, vincristine and prednisone (Mega-CHOP) for non-Hodgkin lymphoma”. Hum. Reprod., 2005, 20, 2247.

[30] Recchia F., Saggio G., Amiconi G., Di Blasio A., Cesta A., Candeloro G., Rea S.: “Gonadotropin-releasing hormone analogues added to adjuvant chemotherapy protect ovarian function and improve clinical outcomes in young women with early breast carcinoma”. Cancer, 2006, 106, 514.

[31] Huser M., Crha I., Hudecek R., Ventruba P., Zakova J., Smardova L., Kral Z.: “Ovarian tissue cryopreservation”. Eur. J. Gynaecol. Oncol., 2007, 28, 249.

Abstracted / indexed in

Science Citation Index Expanded (SciSearch) Created as SCI in 1964, Science Citation Index Expanded now indexes over 9,500 of the world’s most impactful journals across 178 scientific disciplines. More than 53 million records and 1.18 billion cited references date back from 1900 to present.

Biological Abstracts Easily discover critical journal coverage of the life sciences with Biological Abstracts, produced by the Web of Science Group, with topics ranging from botany to microbiology to pharmacology. Including BIOSIS indexing and MeSH terms, specialized indexing in Biological Abstracts helps you to discover more accurate, context-sensitive results.

Google Scholar Google Scholar is a freely accessible web search engine that indexes the full text or metadata of scholarly literature across an array of publishing formats and disciplines.

JournalSeek Genamics JournalSeek is the largest completely categorized database of freely available journal information available on the internet. The database presently contains 39226 titles. Journal information includes the description (aims and scope), journal abbreviation, journal homepage link, subject category and ISSN.

Current Contents - Clinical Medicine Current Contents - Clinical Medicine provides easy access to complete tables of contents, abstracts, bibliographic information and all other significant items in recently published issues from over 1,000 leading journals in clinical medicine.

BIOSIS Previews BIOSIS Previews is an English-language, bibliographic database service, with abstracts and citation indexing. It is part of Clarivate Analytics Web of Science suite. BIOSIS Previews indexes data from 1926 to the present.

Journal Citation Reports/Science Edition Journal Citation Reports/Science Edition aims to evaluate a journal’s value from multiple perspectives including the journal impact factor, descriptive data about a journal’s open access content as well as contributing authors, and provide readers a transparent and publisher-neutral data & statistics information about the journal.

Submission Turnaround Time